Entasis Therapeutics to Participate in H.C. Wainwright BioConnect 2022
January 10, 2022 08:00 ET
|
Entasis Therapeutics Holdings Inc.
WALTHAM, Mass., Jan. 10, 2022 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc. (NASDAQ: ETTX), a late-stage clinical biopharmaceutical company focused on the discovery and development of novel...
Entasis Therapeutics Announces Third Quarter 2021 Financial Results and Provides Business Update
November 04, 2021 07:30 ET
|
Entasis Therapeutics Holdings Inc.
Sulbactam-durlobactam (SUL-DUR) achieved all primary and secondary endpoints from landmark Phase 3 ATTACK trialRobust dataset builds compelling case for SUL-DUR which if approved, could become the...
Entasis Therapeutics to Report Third Quarter 2021 Results and Host Conference Call November 4, 2021
October 28, 2021 08:00 ET
|
Entasis Therapeutics Holdings Inc.
WALTHAM, Mass., Oct. 28, 2021 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc. (NASDAQ: ETTX), a late-stage clinical biopharmaceutical company focused on the discovery and development of novel...
Entasis Therapeutics announces positive topline results for sulbactam-durlobactam (SUL-DUR) from Phase 3 ATTACK trial
October 18, 2021 16:05 ET
|
Entasis Therapeutics Holdings Inc.
SUL-DUR first to achieve statistical non-inferiority in 28-day all-cause mortality in carbapenem-resistant Acinetobacter (CRAB) patientsStatistically significant difference in clinical cure at Test of...
Entasis Therapeutics to Participate in the Cantor Fitzgerald Virtual Global Healthcare Conference
September 23, 2021 16:05 ET
|
Entasis Therapeutics Holdings Inc.
WALTHAM, Mass., Sept. 23, 2021 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc. (NASDAQ: ETTX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel...
Profile of Entasis Therapeutics ETX0462 Candidate Published in the Journal Nature
September 15, 2021 16:01 ET
|
Entasis Therapeutics Holdings Inc.
WALTHAM, Mass., Sept. 15, 2021 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc. (NASDAQ: ETTX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel...
Entasis Therapeutics to Participate in the H.C. Wainwright 23rd Annual Global Investment Conference
September 09, 2021 08:00 ET
|
Entasis Therapeutics Holdings Inc.
WALTHAM, Mass., Sept. 09, 2021 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc. (NASDAQ: ETTX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel...
Entasis Therapeutics Reports Second Quarter 2021 Financial Results and Provides Business Update
August 11, 2021 16:05 ET
|
Entasis Therapeutics Holdings Inc.
-Management to Host Conference Call on August 12 at 8am ET- Patient Enrollment in the ATTACK Phase 3 Registrational Trial Completed; Top-Line Data Readout Expected Early Fourth Quarter 2021SUL-DUR...
Entasis Therapeutics to Host Expert Perspectives Webinar on Acinetobacter Infections
August 10, 2021 08:00 ET
|
Entasis Therapeutics Holdings Inc.
– Virtual Event to be Held Tuesday, August 24 at 10am Eastern Time – WALTHAM, Mass., Aug. 10, 2021 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc. (NASDAQ:ETTX), a clinical-stage...
Entasis Therapeutics to Report Second Quarter 2021 Results and Host Conference Call August 12, 2021
August 05, 2021 16:01 ET
|
Entasis Therapeutics Holdings Inc.
WALTHAM, Mass., Aug. 05, 2021 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc. (NASDAQ: ETTX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel...